RJA
AH

Raymond James & Associates’s Accretive Health AH Stock Holding History

Raymond James & Associates’s Portfolio AH Stock Details AH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-22,285
Closed -$203K – 2080
2013
Q3 		$203K Sell
22,285
-4,950
-18% -$49.2K ﹤0.01% 1896
2013
Q2 		$294K Buy
+27,235
New +$287K ﹤0.01% 1715

Other funds holding AH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JRP
Jasper Ridge Partners Menlo Park, California $4.69B AUM 31.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CII
CR Intrinsic Investors Stamford, Connecticut $2.67B AUM 28.43% 1-Year Est. Return

Raymond James & Associates's AH Position: Q4 2013 in Review

Raymond James & Associates sold out of Accretive Health (AH) in Q4 2013, closing a stake of 22,285 shares — an estimated $203K sold.

Raymond James & Associates first reported a position in AH in Q2 2013 and held it in 2 quarters. The position peaked at $294K in Q2 2013. 85 funds tracked by Wall St. Rank hold AH as of Q4 2013.

  • Raymond James & Associates reported no remaining Accretive Health position as of Q4 2013 after selling out during the quarter.
  • Raymond James & Associates sold 22,285 Accretive Health shares in Q4 2013, an estimated $203K.
  • Raymond James & Associates first reported a position in Accretive Health in Q2 2013 and held it in 2 quarters.
  • Raymond James & Associates's Accretive Health position peaked at $294K in Q2 2013.
  • 85 funds tracked by Wall St. Rank held Accretive Health as of Q4 2013.

Based on Raymond James & Associates's 13F filing for Q4 2013, filed 13 Feb 2014.